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Abstract 
Background Lymph node (LN), peripheral blood  (PB) and bone marrow (BM) samples are commonly 
analyzed by flow cytometry (FC) for the immunophenotyping and staging of canine lymphomas. A 
prognostic value for flow cytometric BM infiltration in dogs with large B-cell lymphoma (LBCL) was 
demonstrated. Aim of the present study was to define the analytical performances of this technique, and to 
establish a cutoff suitable to safely discriminate between infiltrated and non-infiltrated PB and BM samples. 
Methods Large B-cells were added to control PB and BM samples, to achieve twelve different large B-cells 
concentrations, ranging from 0% to 50%. The percentage of large B-cells was recorded for each dilution, 
using a BD Accuri C6 flow cytometer. Accuracy was evaluated by Passing-Bablok regression analysis. Intra-
assay precision was assessed at 0%, 1%, 3% and 10% dilutions evaluating the CVs of ten repeated 
acquisitions. ROC curves were drawn to identify the cutoffs most suitable to discriminate between 25 
infiltrated (PARR-positive) and 25 non-infiltrated (PARR-negative) PB and BM samples, respectively. 
Results Optimal analytical accuracy and precision were achieved. Almost all CVs were <10%. Negative 
controls had up to 0.5% large B-cells, with 50% and 22% CV in PB and BM samples, respectively. 0.56% and 
2.45% cutoffs were selected based on the ROC curves for PB and BM samples, respectively. 
Conclusions Quantification of large B-cells in PB and BM samples by FC is reliable and analytical 
performances met the acceptance criteria. Assessment of performances of different instruments and 
protocols is warranted. 
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Introduction 
Increasing interest in canine lymphoma by the scientific literature has been observed in the recent years for 
two reasons. The first is the high prevalence in dogs, and the second is the possible identification of the dog 
as spontaneous animal model to study lymphoma in humans (1-4).  
However, diagnostic, staging and treatment protocols are not standardized in veterinary medicine, thus 
preventing the comparison of results from different studies and reducing the scientific value of the canine 
model. Indeed, as innovative and more sensitive staging methods are introduced, dogs may be reclassified 
as having a higher disease staging (5).  
In this contest, peripheral blood (PB) and bone marrow (BM) infiltration have been assessed alternatively 
by cytology (5-8), flow cytometry (FC) (9-12) or PCR for antigen receptor rearrangements (PARR) (13), but 
only FC has been demonstrated to have a prognostic relevance in dogs with large B-cell lymphoma (LBCL) 
(11). PB and BM infiltration were quantified as the percentage of large B-cells on the total CD45-positive 
cells. Further, BM infiltration was negatively correlated with time to progression and lymphoma specific 
survival and a cut-off of 3% infiltration was the best value to discriminate between two prognostic groups. 
Despite its efficacy to discriminate dogs with different prognosis, analytical performances of this FC 
strategy have never been assessed. 
The aim of the present study was to explore the applicability of FC for the evaluation of PB and BM 
infiltration in dogs with LBCL. In particular, we aim to:  1) assess analytical sensitivity, precision and 
accuracy; 2) select a cut-off percentage of large B-cells suitable to safely discriminate between infiltrated 
and non-infiltrated PB and BM samples. 
Materials and methods 
Samples included in the study were sent by private veterinarians to the Laboratory of the Department of 
Veterinary Sciences (University of Turin, Grugliasco, Turin) for diagnostic purposes or routine haematology 
analysis, and analyzed within 24 hours from sampling. All dogs were privately owned and sampled for 
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diagnostic purposes with the informed consent of owners. Thus, a formal approval of the Institution 
Committee for Animal Care of the University of Turin was not necessary. 
Flow cytometry 
Sample processing for FC was performed as previously described (14). Lymph node aspirates (LN) were 
collected in RPMI 1640 tubes, whereas PB and BM samples were collected in EDTA tubes. Prior to labelling, 
all samples were counted via an automated haematology analyzer (ADVIA 120, Siemens Healthcare 
Diagnostics, Milan, Italy) to assess cellularity and underwent RBC lysis with an erythrocytes lysis buffer 
containing 8% ammonium chloride. After washing, cells were resuspended in RPMI 1640 medium, 
containing 5% fetal bovine serum. For surface marker labelling, 1 x10
6
 cells/tube were incubated with 
different combinations of the following antibodies: CD5-FITC (clone YKIX322.3), CD3-FITC (clone 
CA17.2A12), CD4-FITC (clone YKIX302.9), CD8-PE (clone YCATE55.9), CD21-PE (clone CA2.1D6), cyCD79b-
FITC (clone AT107), CD45-AlexaFluor647 (clone YKIX716.13). Isotype-matched controls were included for 
each labelling. All antibodies were previously titered to determine the best working dilution. All antibodies 
were from AbD Serotec (Oxford, UK). After incubation of 20 minutes at 4°C, samples were washed twice in 
RPMI 1640 and finally resuspended in 500 µl PBS for acquisition. 
Samples were acquired with a BD Accuri C6 (Becton Dickinson, San Josè, CA, USA). For each sample, a 
minimum of 10,000 cells was acquired, with an acquisition rate of less than 2,000 events/second. Analyses 
were performed with a specific software (CFlow Plus, Becton Dickinson, San Josè, CA, USA) by one operator 
(FR). Cells were visualized at first in a FSC vs SCC morphological dot plot, and a gate (R1) was set to exclude 
platelets and debris. R1 cells were then visualized based on FSC and CD45 expression. Further analyses 
were performed including only R1 CD45-positive cells. 
The diagnosis of LBCL was achieved when LN cytological findings were compatible with high-grade B-cell 
lymphoma according to updated Kiel classification scheme (15) and more than 80% of CD45-positive cells in 
the LN were large-sized (FSC-H > 2,000,000) and co-expressing CD21. To assess PB and BM infiltration, 
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CD45-positive R1 cells were visualized based on FSC and CD21 expression: infiltration was defined as the 
percentage of large CD21-positive cells out of total CD45 cells (11) (Figure 1). 
Analytical validation 
Dilution experiments were performed by adding LN neoplastic cells from dogs with LBCL to PB and BM 
samples from one healthy dog and one dog with a disease different from lymphoma (mast cell tumour), 
respectively. A single dilution experiment for each matrix (PB and BM) was performed. Dilution volumes 
were calculated in order to have neoplastic cells accounting for 50%, 25%, 10%, 7%, 5%, 3%, 2%, 1%, 0,5%, 
0,4% and 0,3% out of total CD45-positive cells. To this aim, a multi-step mathematical calculation was done, 
including the following parameters: expected large B-cells percentage, LN and PB/BM cellularity assessed 
by the haematology analyser, percentage of large B-cells and of other non-neoplastic cells in the LN and 
PB/BM sample assessed via FC, total number of cells/tube desired. Finally, PBS 1x was added to each tube, 
to fill to a final volume of 100 µl. All samples were acquired immediately after preparation. Agreement 
between expected and obtained percentages was evaluated by Passing-Bablok regression analysis 
(Analyse-it, Analyse-it Software Ltd, Leeds, UK). 
Negative controls (i.e. PB and BM samples prior to neoplastic cells addition), 1%, 3% and 10% samples were 
acquired ten-times to assess intra-assay precision as measured by the Coefficient of Variation (CV). 
Sensitivity was defined as the percentage of neoplastic cells to be added to exceed the Limit Of Detection 
(LOD) in negative controls. The LOD was defined as mean + 3 Standard Deviation (SD) of all negative 
controls included in the present study (16-17). 
Diagnostic validation 
Two ROC curves were drawn with SPSS Statistics for Windows 17.0 (SPSS Inc, Chicago, USA), to select the 
large B-cells cut-off value most suitable to discriminate between infiltrated and non-infiltrated PB and BM 
samples. PARR-positive PB and BM samples from dogs with LBCL were regarded as truly infiltrated samples, 
whereas PARR-negative PB and BM samples from healthy dogs or dogs with diseases other than LBCL were 
regarded as truly negative samples. PARR analysis was performed according to already published protocols 
This article is protected by copyright. All rights reserved.
6 
 
(18) on LN, PB and BM samples stored at -20°C until the analysis day. The cut-offs were selected based on 
the best compromise between sensitivity and specificity in PB and BM samples, respectively. 
Results 
Analytical validation 
Results from dilution experiments are listed in Table 1. Passing-Bablok regression analysis revealed an 
optimal agreement between expected and obtained percentages. In particular, no significant error was 
detected in PB dilutions (intercept 0.00, 95% CI 0.00-0.00; slope 1.00, 95% CI 0.93-1.05), whereas a slight 
proportional error was detected in BM dilutions (intercept 0.00, 95% CI 0.00-0.00; slope 0.89, 95% CI 0.80-
0.95) (Figure 2). 
Intra-assay precision parameters are listed in Table 2. 
LOD was 0.470 and 1.125 in the PB and BM negative controls, respectively. A minimum of 0.5% and 2% 
large B-cells had to be added to PB and BM samples to exceed these values, respectively (Table 1). These 
values were therefore considered the lower detection limit for PB and BM samples, respectively. 
Diagnostic validation 
Overall, 50 samples were used to draw each ROC curve, including 25 positive and 25 negative samples. PB 
negative samples included: 7 healthy dogs, 4 dogs with Leishmaniasis, 2 dogs with atopic dermatitis, 2 dogs 
with pyoderma, 2 dogs with T-cell lymphoma, 2 dogs with periodontitis, and 1 dog each with disseminated 
histiocytic sarcoma, Evans syndrome, immune-mediated thrombocytopenia, mast cell tumour, melanoma 
and osteosarcoma. Mean large B-cell percentage in the negative samples was 0.109±0.120% (median 
0.08%, range 0.01-0.6%); mean large B-cell percentage in the positive samples was 10.550±18.765% 
(median 3.13%, range 0.2-83.6%). The ROC curve identified a 0.41% large B-cells percentage as the best 
cut-off to discriminate between positive and negative PB samples, with a 96% sensitivity and a 96% 
specificity. This value was below the lower detection limit. Among values exceeding the lower detection 
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limit, 0.56% large B-cells was the one associated with the best compromise between sensitivity (92%) and 
specificity (96%). 
BM negative samples included: 7 dogs with regenerative anaemia, 7 dogs with T-cell lymphoma, 4 dogs 
with Leishmaniasis, 2 dogs with Evans syndrome and 1 dog each with disseminated histiocytic sarcoma, 
immune-mediated neutropenia, lymph node reactive hyperplasia of unknown origin, mast cell tumour, 
multiple myeloma. The mean percentage of large B-cells in the negative samples was 0.340±0.267% 
(median 0.3%, range 0.1-1.43%); the mean percentage of large B-cells in the positive samples was 
11.730±18.031% (median 3.9%, range 0.45-73.6%). The ROC curve identified a 0.77% large B-cells 
percentage as the best cut-off to discriminate between positive and negative BM samples, with a 96% 
sensitivity and a 96% specificity. This value was below the lower detection limit. Among values exceeding 
the lower detection limit, 2.45% large B-cells was the one associated with the best compromise between 
sensitivity (68%) and specificity (100%). 
Discussion 
Different techniques have been used in the published literature to assess PB and BM infiltration in dogs 
with lymphoma. However, only BM infiltration quantified by FC has proved to be prognostically relevant 
(11). The present study describes the analytical performances of the FC strategy routinely used in 
veterinary medicine. In addition, we identify the percentage cut-offs of large B-cells best discriminating 
between infiltrated and non-infiltrated samples. 
Based on our results, FC accurately quantifies neoplastic large B-cells in canine PB and BM samples. Indeed, 
only a slight proportional error in BM dilutions was found. Although causes for this slight error are not neat 
to the authors, this may be associated to pre-analytical factors, such as manual dilutions preparation, or to 
the presence of stromal or adipose cells either in the LN or in the BM sample that were counted by the 
haematology analyzer but were not included in the FC gates. However, this proportional error has only a 
tenuous clinical relevance, since it affects only high infiltration values, which are uncommon in canine LBCL 
(11,12) and far from the prognostically relevant cut-off of 3% (11). 
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We also assessed analytical precision of our FC strategy, by calculating the CVs for negative controls and for 
three different infiltration levels. Different methods have been proposed in the published literature to 
assess whether the analytical imprecision of a laboratory test may be considered acceptable, correlating 
analytical CV to the Total Error Allowable (TEA), that is the total amount of error medically, administratively 
or legally acceptable (19). The calculation of TEA is based on biological variations. To date, there are no 
data concerning biological variations in the percentage of large B-cells in canine PB or BM samples: thus, it 
is not possible to evaluate the CVs obtained by the present study with traditional methods. Still, a few 
considerations can be done. First, because only a 3% BM infiltration is considered clinically relevant (11), 
and the CVs obtained for this percentage in the present study are low, they might be tentatively considered 
acceptable. Second, high CV values were obtained only for negative controls, but still, large B-cells 
percentages in the negative controls were always much lower than 3%, thus clinical decisions would not be 
affected.  However, further studies are needed, including repeated samples from healthy dogs and from 
dogs of different breeds, to assess the individual and the inter-breed variability and define the most 
appropriate TEA. 
We identified a sensitivity of 0.5% and 2% for our FC strategy applied to PB and BM samples, respectively. 
The sensitivity of FC is influenced by many variables. First, it increases in parallel with the number of 
evaluated parameters and antigen expression. Unfortunately, this is hard to achieve in veterinary medicine 
because of the paucity of validated antibodies cross-reacting with canine antigens. In particular, canine B-
cell markers that may be investigated via FC are mostly represented by intracellular molecules or 
cytoplasmic portion of intra-membrane proteins: permeabilization procedures are then required, which are 
time-consuming, enhance costs and are therefore of scarce applicability to clinical diagnostic assays. 
Validation of new antibodies is warranted, to get a more detailed finger-print of neoplastic cells and to 
improve sensitivity in staging procedures. Second, sensitivity varies with the number of acquired events. In 
the present study, we acquired 10,000 cells/tube in order to follow as closely as possible the procedures 
described in literature and applied by most of the veterinary diagnostic laboratories.  However, we support 
the opportunity of acquiring a higher number of events (up to 100,000) to analyze clinical specimens where 
only a low number of neoplastic cells is detected, in order to improve sensitivity. 
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Beside analytical validation, we also managed to detect a large B-cells cut-off suitable to safely discriminate 
between infiltrated and not-infiltrated PB and BM samples. In the absence of an officially recognized gold 
standard, PARR-positive samples were considered as truly infiltrated because PARR is more sensitive than 
FC in detecting infiltrated samples at diagnosis (18). Unfortunately, false negative PARR results have also 
been reported in dogs with lymphoma (20,21): thus, PB or BM infiltration should not be excluded based on 
PARR-negative results and these samples could not be considered as truly not-infiltrated. That being so, we 
only considered PARR-negative samples from healthy dogs or dogs with other diseases as truly negative 
samples.  
Several studies in human medicine described the use of FC to stage B-cell lymphomas. High agreement 
between FC and BM biopsy (BMB) results has been reported, although also FC-positive BMB-negative and 
FC-negative BMB-positive cases might occur (22-24). However, differently from the present study, the FC 
strategy used in human medicine is based on the calculation of κ/λ ratio (light chain restriction). 
Unfortunately, this approach is ineffective in the canine species, since even healthy dogs have 90% λ chain 
and a restricted ratio (25). In addition, most commonly applied diagnostic criteria vary between human and 
canine lymphomas. Indeed, histopathological evaluation is mandatory under official guidelines in human 
medicine (26), whereas it is not commonly performed in dogs when a cytological diagnosis of high-grade 
lymphoma has been obtained, as documented by a recent survey among veterinary oncologists (27). Given 
these circumstances, in the present study the diagnosis of LBCL was made based only on neoplastic cells 
cytological appearance and FC phenotype, even if different lymphoma subtypes may have been included. 
The main pitfall of the present study is that the research protocol has been performed by one operator, 
with one single flow cytometer associated to a specific software. Thus, our results may not be expandable 
to other laboratories, since slight operator-to-operator or machine-to-machine variability is possible (28). 
However, this is the first study doing this approach representing a milestone for other FC facility to assess 
analytical and diagnostic performances. 
In conclusion, the present study describes a FC strategy to quantify PB and BM neoplastic cells infiltration in 
dogs with LBCL and analytical and diagnostic performances met the acceptance criteria. Validation of 
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laboratory methods to stage canine lymphoma is relevant not only from a veterinary point of view, but also 
from a comparative perspective, since the dog is increasingly regarded as a valid animal model to study 
human lymphoma (1-4). 
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Table 1: Percentages of large B-cells obtained diluting lymph nodal neoplastic cells from a dog with large B-
cell lymphoma into negative peripheral blood and bone marrow controls at different concentrations 
Expected large B-cell 
concentration (%) 
Obtained large B-cell concentration (%) 
Peripheral blood Bone marrow 
Negative control 0.230 (CV=50.413%)* 0.420 (CV=21.879%)* 
0.3 0.4 Nt 
0.4 0.4 0.5 
0.5 0.6 0.8 
1 1.030 (CV=9.211%)* 0.950 (CV=10.230%)* 
2 1.6 1.5 
3 2.900 (CV=3.635%)* 2.890 (CV=7.194%)* 
5 5.3 3.9 
7 7.1 6 
10 9.500 (CV=3.746%)* 9.870 (CV=2.484%)* 
25 27.8 23.4 
50 49.9 44.7 
*=mean value of ten repeated measurements; Nt= not tested 
  
This article is protected by copyright. All rights reserved.
15 
 
Table 2: Intra-assay precision of large B-cells quantification in dilutions of lymph node neoplastic cells from 
a dog with large B-cell lymphoma into negative peripheral blood and bone marrow controls 
Expected large B-cell 
concentration (%) 
PB dilutions BM dilutions 
mean±SD CV (%) mean±SD CV 
Negative control 0.230±0.116 50.413 0.420±0.092 21.879 
1 1.030±0.095 9.211 0.950±0.097 10.230 
3 2.900±0.105 3.635 2.890±0.208 7.194 
10 9.500±0.356 3.746 9.870±0.245 2.484 
PB= peripheral blood; BM= bone marrow; SD=standard deviation; CV= coefficient of variation 
 
 
Figure 1: scatter plots representing our gating strategy. Cells were visualised at first in a FSC vs SCC 
morphological dot plot and a gate (R1) was set to exclude platelets and debris. R1 cells were then visualized 
based on FSC and CD45 expression. Finally, CD45-positive R1 cells (Q3-UR) were visualized based on FSC 
and CD21 expression. Sample infiltration was defined as the percentage of large CD21-positive cells out of 
total CD45-positive cells. 
Figure 2: results from Passing-Bablok regression analyses performed to assess the agreement between 
expected and obtained large B-cells percentages in dilution experiments. A: peripheral blood dilution 
experiments; no error was detected. B: bone marrow dilution experiments; a slight proportional error was 
found. 
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